Advertisement
BCRX vs CLDX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and CLDX is a Hold.
BCRX sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for BCRX moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCRX as a result. In 81 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for BCRX turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 40 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
BCRX broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BCRX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BCRX's RSI Indicator exited the oversold zone, 29 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCRX advanced for three days, in 202 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.326) is normal, around the industry mean (6.379). P/E Ratio (-5.696) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (2.097) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. BCRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
CLDX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CLDX turned positive on October 19, 2026. Looking at past instances where CLDX's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLDX's RSI Indicator exited the oversold zone, 23 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CLDX as a result. In 67 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +10.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDX advanced for three days, in 205 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 50-day moving average for CLDX moved below the 200-day moving average on November 10, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
CLDX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CLDX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. CLDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.283) is normal, around the industry mean (3.498). P/E Ratio (-6.867) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. CLDX's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
BCRX | CLDX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 17 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 63 | 58 | |
P/E GROWTH RATING 1..100 | 98 | 25 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BCRX's Valuation (11) in the Biotechnology industry is significantly better than the same rating for CLDX (99). This means that BCRX’s stock grew significantly faster than CLDX’s over the last 12 months.
BCRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CLDX (100). This means that BCRX’s stock grew similarly to CLDX’s over the last 12 months.
CLDX's SMR Rating (98) in the Biotechnology industry is in the same range as BCRX (100). This means that CLDX’s stock grew similarly to BCRX’s over the last 12 months.
CLDX's Price Growth Rating (58) in the Biotechnology industry is in the same range as BCRX (63). This means that CLDX’s stock grew similarly to BCRX’s over the last 12 months.
CLDX's P/E Growth Rating (25) in the Biotechnology industry is significantly better than the same rating for BCRX (98). This means that CLDX’s stock grew significantly faster than BCRX’s over the last 12 months.
| BCRX | CLDX | |
|---|---|---|
| RSI ODDS (%) | 6 days ago 83% | 1 day ago 68% |
| Stochastic ODDS (%) | 1 day ago 76% | 1 day ago 74% |
| Momentum ODDS (%) | 1 day ago 84% | 1 day ago 79% |
| MACD ODDS (%) | 1 day ago 74% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 79% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 76% |
| Advances ODDS (%) | 14 days ago 77% | 3 days ago 77% |
| Declines ODDS (%) | 2 days ago 79% | 1 day ago 78% |
| BollingerBands ODDS (%) | 1 day ago 83% | 1 day ago 88% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCRX’s FA Score shows that 1 FA rating(s) are green while CLDX’s FA Score has 1 green FA rating(s).
- BCRX’s FA Score: 1 green, 4 red.
- CLDX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCRX’s TA Score shows that 3 TA indicator(s) are bullish while CLDX’s TA Score has 4 bullish TA indicator(s).
- BCRX’s TA Score: 3 bullish, 6 bearish.
- CLDX’s TA Score: 4 bullish, 5 bearish.
Price Growth
BCRX (@Pharmaceuticals: Generic) experienced а -7.16% price change this week, while CLDX (@Biotechnology) price change was +0.74% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.13%. For the same industry, the average monthly price growth was -6.49%, and the average quarterly price growth was +10.54%.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
BCRX is expected to report earnings on Feb 24, 2027.
CLDX is expected to report earnings on Mar 01, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.13% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
BCRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To BCRX | 1D Price Change % | ||
|---|---|---|---|---|
| BCRX | 100% | +1.59% | ||
| VCYT - BCRX | 46% Loosely correlated | +4.36% | ||
| HOWL - BCRX | 39% Loosely correlated | +1.95% | ||
| ROIV - BCRX | 38% Loosely correlated | +1.60% | ||
| BEAM - BCRX | 38% Loosely correlated | +2.62% | ||
| CLDX - BCRX | 37% Loosely correlated | -1.63% | ||
More | ||||
CLDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with STOK. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then STOK could also see price increases.
| Ticker / NAME | Correlation To CLDX | 1D Price Change % | ||
|---|---|---|---|---|
| CLDX | 100% | -1.63% | ||
| STOK - CLDX | 48% Loosely correlated | +2.02% | ||
| MGTX - CLDX | 47% Loosely correlated | +0.62% | ||
| VYGR - CLDX | 46% Loosely correlated | -3.56% | ||
| LXEO - CLDX | 45% Loosely correlated | +0.33% | ||
| RXRX - CLDX | 45% Loosely correlated | +1.13% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QUSA | 16.28 | 0.31 | +1.94% |
| Vistashares Target 15 Usa Quality Income ETF | |||
| XCOM | 24.15 | N/A | N/A |
| Corgi All Commodities 2x Daily ETF (XCOM) | |||
| LTPZ | 46.10 | -0.04 | -0.09% |
| PIMCO 15+ Year US TIPS Index Exchange-Traded Fund (LTPZ) | |||
| EIRL | 83.64 | -0.47 | -0.56% |
| iShares MSCI Ireland ETF (EIRL) | |||
| OIA | 5.74 | -0.06 | -1.03% |
| INVESCO Municipal Income OPPORTUNITIES TRUST | |||